Transformative Diagnostics



Next-Generation Therapies & Vaccines

Addressing large, unmet global markets with innovative proprietary products More »


Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »


Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

Chairman’s Message

OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.



 OPKO Completes Acquisition of Bio-Reference Laboratories.



OPKO Letter to Shareholders»

News & Events

more news »

OPKO Health Enters Companion Animal Health Market more »

OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx more »

OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference more »


read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.



FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »